Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Immunological biomarkers and TARC/CCL17 in myelodysplastic syndrome: Insights into immune microenvironment regulation

View Full Paper
Ask AI
Bookmark
Share

Authors

PTPınar TığlıoğluAYAsu Fergün Yılmaz

Discussion

Loading...

Member takes

Overview

Analysis reveals no significant changes in inflammatory cytokines among MDS patients, suggesting limitations of peripheral biomarkers.

Key Points

  • Intermediate-high risk MDS patients showed no systemic immune activation through circulating cytokines.
  • IL-6, proinflammatory cytokines, and other chemokines demonstrated similar levels in patients and controls.
  • Analysis utilizing the International Prognostic Scoring System identified no significant immune dysregulation markers.
  • Findings challenge the role of peripheral biomarkers in assessing the immune landscape in MDS, emphasizing localized assessments.

Cite This Study

Tığlıoğlu et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d508https://doi.org/10.1182/blood-2025-7359
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS2025
  2. 2Bone marrow immune and stromal niche remodeling in myelodysplastic neoplasm patients under erythropoietic therapies by 29-color full-spectrum flow cytometry2025
  3. 3Distinct distributions of lymphocyte subsets in myelodysplastic syndrome correlate with risk stratification2025
  4. 4Interferon-gamma production in the bone marrow of myelodysplastic syndrome patients supports a treg-independent immune-tolerant microenvironment2025
  5. 5Improving MDS Risk Assessment: The Role of Monocytopenia and Lymphocytopenia Beyond IPSS-R2025 · 1 citations